Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1423P - Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy

Date

21 Oct 2023

Session

Poster session 20

Topics

Radiological Imaging

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Anita Bolina

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

A. Bolina1, M. Sallam2, A. Ortega Franco3, H. Wong4, D. Cobben5, C. Escriu6

Author affiliations

  • 1 Medical Oncology, University of Liverpool, L69 3GF - Liverpool/GB
  • 2 Internal Medicine, Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust, B15 2TH - Birmingham/GB
  • 3 Medical Oncology, Cancer Research UK Manchester Institute - The University of Manchester, SK10 4TG - Macclesfield/GB
  • 4 Biostatistics, The Clatterbridge Cancer Centre - Liverpool, L7 8YA - Liverpool/GB
  • 5 Radiation Oncology, The Clatterbridge Cancer Centre - Liverpool, L7 8YA - Liverpool/GB
  • 6 Medical Oncology, The Clatterbridge Cancer Center - Liverpool, L7 8YA - Liverpool/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1423P

Background

Lymphangitic carcinomatosis (LC) is a pathological feature secondary to lymphatic or haematological spread, without an immune cell infiltrate but with radiological appearances of inflammation. Immunotherapy (IO) is now standard of care in early and late-stage non-small cell lung cancer (NSCLC). LC correlates with poor prognosis, but its effects on immunotherapy response are unknown. Here we aim to explore the predictive relevance of the radiological diagnosis of LC in patients with advanced NSCLC treated with single agent immunotherapy (SAIO) or with chemo-immunotherapy (CIO).

Methods

Demographic and clinical data of patients treated with first-line IO between January 2016 and December 2020 was retrospectively collected, and patients with LC identified using pre-treatment CT reports. A paired control arm matched for gender, age (≤70 or >70), smoking status, PS, PDL1 (<1%, 1-49% and ≥50%), stage and treatment was used to compare clinical outcomes. Chi-square Log-Rank (Mantel-Cox) test was used to compare Progression-Free Survival (PFS) and Overall Survival (OS).

Results

A total of 484 patients had been treated with first-line SAIO or CIO, 46 (10.6%) with LC. 41 of them (89%) had non-squamous histology. 29 (63%) were treated with SIAO and 17 (37%) with CIO. Comparing tumours with LC versus the rest, PDL1 expression was <1%; 24 vs 11%, 1-49%; 9 vs 11% and ≥50%; 65 vs 71%. Grade 3/4 IO toxicity rates were similar (48% vs 45%). Comparing patients with LC versus a paired control population (n=73), overall response rates were 28% vs 56%, with disease progression rates of 37 vs 25%. Median PFS was 5 vs 9 months (HR 1.57, 95% C.I. 1.054 – 2.35, p=0.019) and median OS was 9 vs 17 months (HR 1.49, 95% C.I. 0.995 – 2.224, p=0.046). Brain metastases on progression were more common in patients with LC (20% vs 8%). Using univariate Cox regression analysis, PFS and OS were not influenced by the treatment received (SAIO or CIO).

Conclusions

Lymphangitis Carcinomatosis (LC) in patients with NSCLC treated with immunotherapy correlated with lower response rates, poorer PFS and OS. Addition of chemotherapy did not improve outcomes. LC may represent a pre-treatment marker of primary resistance to immunotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The Clatterbridge Cancer Centre.

Funding

Has not received any funding.

Disclosure

C. Escriu: Financial Interests, Personal, Advisory Board: MSD, Roche; Financial Interests, Personal, Invited Speaker: MSD, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.